We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Editing Used to Correct Mitochondrial Mutations

By LabMedica International staff writers
Posted on 08 Oct 2018
A recently developed mouse model, which mimics a cardiac mitochondrial disease, was used to demonstrate the potential use of genomic engineering to treat the disorder by eliminating the mutation that causes it.

Mitochondrial diseases are, as the name implies, a group of disorders caused by dysfunctional mitochondria. More...
About 15% of the time these diseases are caused by mutations in the mitochondrial DNA (mtDNA) that affect mitochondrial function. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. The subclass of these diseases that have neuromuscular disease symptoms are often called a mitochondrial myopathy.

To address the lack of effective treatment for these disorders, investigators at the University of Cambridge (United Kingdom) exploited a recently developed mouse model (the m.5024C>T tRNAAla mouse) that recapitulates common molecular features of heteroplasmic mtDNA disease in cardiac tissue.

To modify the mitochondrial genome, the investigators chose a programmable nuclease therapy approach, using mitochondrially targeted zinc-finger nucleases (mtZFN), rather than the more frequently used CRISPR/Cas9 method. The mtZFN gene-editing tool was delivered to the mice via an adeno-associated virus vector. The tool was designed to recognize and then eliminate mutant mitochondrial DNA, based on sequence differences between healthy and mutant mitochondrial DNA.

The investigators reported in the September 24, 2018, online edition of the journal Nature Medicine that by systemically administering mitochondrially targeted mtZFN using adeno-associated virus to the mice, they successfully induced specific elimination of mutant mtDNA across the heart. The biochemical and physiological behavior of the diseased hearts returned to near normal values.

"One idea for treating these devastating diseases is to reduce the amount of mutated mitochondrial DNA by selectively destroying the mutated DNA, and allowing healthy DNA to take its place," said senior author Dr. Michal Minczuk, program leader at the mitochondrial biology unit of the University of Cambridge.

Related Links:
University of Cambridge


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.